NMSA Signs Long-Term Framework Agreements to Support Cost Recovery Scheme
NMSA Public Relations
The National Medical Supplies Agency (NMSA) has signed Long-Term Cost Recovery Framework Agreements with Angel Biogenics PVT Ltd, BioLab SL Ltd, Tobinco Pharmaceuticals, and Entrance Pharmaceuticals and Research Center to strengthen the procurement and availability of essential medicines and medical consumables.
The two-year agreements establish products, prices, quality specifications, delivery conditions, and other supply requirements in advance, allowing NMSA to place authorized orders as commodities are required under the redesigned MOH Cost Recovery Scheme.
The framework agreements are expected to improve the predictability, efficiency, quality, and accountability of medicine procurement while supporting timely replenishment of essential commodities.
Speaking during the signing ceremonies, NMSA Managing Director, Madam Jatu Josephine Abdulai, emphasized the importance of transparency, collaboration, and continuous improvement in the implementation of the agreements.
“I hope for an honest and smooth partnership between NMSA, Angel Biogenics, BioLab SL Ltd, Tobinco Pharmaceuticals, and Entrance Pharmaceuticals and Research Center.”
The agreements form part of NMSA’s broader efforts to establish sustainable procurement mechanisms and strengthen the continuous availability of quality-assured medicines for health facilities across Sierra Leone.
